Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1993;87:2016-2022

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Redfield, M. M.
Right arrow Articles by Burnett, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Redfield, M. M.
Right arrow Articles by Burnett, J. C., Jr

Circulation, Vol 87, 2016-2022, Copyright © 1993 by American Heart Association


ARTICLES

Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction

MM Redfield, LL Aarhus, RS Wright and JC Burnett Jr
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn.

BACKGROUND. Recent studies have reported that asymptomatic left ventricular dysfunction (ALVD) in humans is characterized by early neurohumoral activation. Specifically, atrial natriuretic factor (ANF) and norepinephrine are activated without activation of the renin- angiotensin-aldosterone system (RAAS). The current study describes hemodynamic and renal function associated with this neurohumoral profile in a canine model of early and presumably "asymptomatic" ventricular dysfunction. We hypothesized that the neurohumoral profile observed in ALVD is associated with preservation of renal function despite significant hemodynamic compromise. METHODS AND RESULTS. ALVD was produced by ventricular pacing at 180 beats per minute for 10 days. Intravascular volume expansion was performed before and after producing ALVD in eight conscious dogs. The model of ALVD was characterized by decreases in ejection fraction (48 +/- 2 to 29 +/- 4%), cardiac output (4.64 +/- 0.29 to 2.89 +/- 0.17 L/min), and mean arterial pressure (119 +/- 4 to 108 +/- 4 mm Hg). Atrial pressures and systemic vascular resistance were increased. ANF (60 +/- 19 to 165 +/- 27 pg/mL) and norepinephrine (382 +/- 127 to 690 +/- 211 pg/mL) were activated, whereas the RAAS was not. Creatinine clearance and sodium excretion (UNa V) were unchanged after producing ALVD. The natriuretic response to volume expansion in ALVD was completely intact, with increases in UNa V similar to that observed with volume expansion in ALVD was completely intact, with increases in UNa V similar to that observed with volume expansion before producing ALVD. CONCLUSIONS. The current study demonstrates that significant ventricular dysfunction with peripheral vasoconstriction can be associated with normal renal function and thus suggests an important functional role for the neurohumoral profile of ALVD in preserving sodium balance.


This article has been cited by other articles:


Home page
HypertensionHome page
L. C. Costello-Boerrigter, G. Boerrigter, G. J. Harty, A. Cataliotti, M. M. Redfield, and J. C. Burnett Jr
Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction
Hypertension, September 1, 2007; 50(3): 481 - 488.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. J. Rodeheffer
Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?
J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. A. Schirger, H. H. Chen, M. Jougasaki, O. Lisy, G. Boerrigter, A. Cataliotti, and J. C. Burnett Jr
Endothelin A Receptor Antagonism in Experimental Congestive Heart Failure Results in Augmentation of the Renin-Angiotensin System and Sustained Sodium Retention
Circulation, January 20, 2004; 109(2): 249 - 254.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R Ferrara, F Mastrorilli, G Pasanisi, S Censi, N D'aiello, A Fucili, M Valgimigli, and R Ferrari
Neurohormonal modulation in chronic heart failure
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D3 - D11.
[Abstract] [PDF]


Home page
CirculationHome page
A. Cataliotti, G. Boerrigter, H. H. Chen, M. Jougasaki, L. C. Costello, T. Tsuruda, S.-C. Lee, L. S. Malatino, and J. C. Burnett Jr
Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure
Circulation, February 5, 2002; 105(5): 639 - 644.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. H. Chen, J. G. Lainchbury, Y. Matsuda, G. J. Harty, and J. C. Burnett Jr
Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure
Hypertension, August 1, 2001; 38(2): 187 - 191.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Kataoka, R. Nohara, R. Hosokawa, T. Hirai, K. Okuda, C. Li-Guang, Y. Fujibayashi, M. Fujita, J. Konishi, and S. Sasayama
Myocardial Lipid Metabolism in Compensated and Advanced Stages of Heart Failure: Evaluation by Canine Pacing Model with BMIPP
J. Nucl. Med., January 1, 2001; 42(1): 124 - 129.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. H. Chen, J. A. Grantham, J. A. Schirger, M. Jougasaki, M. M. Redfield, and J. C. Burnett Jr.
Subcutaneous administration of brain natriuretic peptide in experimental heart failure
J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1706 - 1712.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O. Lisy, M. M. Redfield, S. Jovanovic, M. Jougasaki, A. Jovanovic, H. Leskinen, A. Terzic, and J. C. Burnett Jr
Mechanical Unloading Versus Neurohumoral Stimulation on Myocardial Structure and Endocrine Function In Vivo
Circulation, July 18, 2000; 102(3): 338 - 343.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Solter, D. Sisson, W. Thomas, and L. Goetze
Intrarenal Effects of Ecadotril during Acute Volume Expansion in Dogs with Congestive Heart Failure
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 989 - 995.
[Abstract] [Full Text]


Home page
J Am Coll CardiolHome page
D. L. Dries, D. V. Exner, M. J. Domanski, B. Greenberg, and L. W. Stevenson
The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction
J. Am. Coll. Cardiol., March 1, 2000; 35(3): 681 - 689.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. H. Chen, J. A. Schirger, W. L. Chau, M. Jougasaki, O. Lisy, M. M. Redfield, P. T. Barclay, and J. C. Burnett Jr
Renal Response to Acute Neutral Endopeptidase Inhibition in Mild and Severe Experimental Heart Failure
Circulation, December 14, 1999; 100(24): 2443 - 2448.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.M Power, J Raman, A Dornom, S.J Farish, L.M Burrell, A.M Tonkin, B Buxton, and C.A Alferness
Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy
Cardiovasc Res, December 1, 1999; 44(3): 549 - 555.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Hasenfuss
Animal models of human cardiovascular disease, heart failure and hypertrophy
Cardiovasc Res, July 1, 1998; 39(1): 60 - 76.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Luchner, T. L. Stevens, D. D. Borgeson, M. Redfield, C.-M. Wei, J. G. Porter, and J. C. Burnett Jr.
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure
Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1684 - H1689.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-T. Shen, R. F. Woltmann, S. Appleby, S. Prahalada, S. M. Krause, S. D. Kivilghn, R. G. Johnson, P. K. Siegl, and J. J. Lynch
Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure
Am J Physiol Heart Circ Physiol, February 1, 1998; 274(2): H456 - H466.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Yamamoto, J. C. Burnett Jr., and M. M. Redfield
Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart
Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2406 - H2414.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Luchner, T. L. Stevens, D. D. Borgeson, M. M. Redfield, J. E. Bailey, S. M. Sandberg, D. M. Heublein, and J. C. Burnett
Angiotensin II in the Evolution of Experimental Heart Failure
Hypertension, September 1, 1996; 28(3): 472 - 477.
[Abstract] [Full Text]


Home page
CirculationHome page
H. H. Chen, J. G. Lainchbury, G. J. Harty, and J. C. Burnett Jr
Maximizing the Natriuretic Peptide System in Experimental Heart Failure: Subcutaneous Brain Natriuretic Peptide and Acute Vasopeptidase Inhibition
Circulation, February 26, 2002; 105(8): 999 - 1003.
[Abstract] [Full Text] [PDF]